Last reviewed · How we verify
Intravenous Ketamine
Intravenous Ketamine is a Dissociative anesthetic Small molecule drug developed by Rebecca Price. It is currently FDA-approved. Also known as: Ketalar, ketamine intravenous.
Intravenous ketamine is a small molecule used to manage postoperative pain and treat conditions such as treatment-resistant depression. It has been studied in various clinical trials for its efficacy in these areas, including a comparison study with tramadol for pain management after major upper abdominal surgery.
At a glance
| Generic name | Intravenous Ketamine |
|---|---|
| Also known as | Ketalar, ketamine intravenous |
| Sponsor | Rebecca Price |
| Drug class | Dissociative anesthetic |
| Target | NMDA receptors |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
Pipeline indications
Boxed warnings
- Risk of psychological dependence
- Potential for abuse
- Dissociative effects
Common side effects
Drug interactions
- MAOIs
- Other CNS depressants
- Antihypertensives
Key clinical trials
- Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
- Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery (PHASE1)
- Randomized Trial of Sedative Choice for Intubation (PHASE4)
- Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP) (EARLY_PHASE1)
- Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients (PHASE4)
- Ketamine + Cognitive Training for Suicidality in the Medical Setting (PHASE4)
- Ketamine for Veterans With Parkinson's Disease (PHASE2)
- Ketamine Treatment of Youth Suicide Attempters (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
| US123456789 |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Ketamine CI brief — competitive landscape report
- Intravenous Ketamine updates RSS · CI watch RSS
- Rebecca Price portfolio CI
Frequently asked questions about Intravenous Ketamine
What is Intravenous Ketamine?
Who makes Intravenous Ketamine?
Is Intravenous Ketamine also known as anything else?
What drug class is Intravenous Ketamine in?
What development phase is Intravenous Ketamine in?
What does Intravenous Ketamine target?
Related
- Drug class: All Dissociative anesthetic drugs
- Target: All drugs targeting NMDA receptors
- Manufacturer: Rebecca Price — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Also known as: Ketalar, ketamine intravenous
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing